Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974430 | 0.84 | MAOA (0.36) | RXFP1KDM4EALDH1A1HPGDSIRT2 | |
| SCHEMBL15764953 | 0.84 | AQP1 (0.39) | SIRT2 | |
| SCHEMBL15758227 | 0.79 | HPGD (0.34) | RXFP1ALDH1A1HPGDSIRT2 | |
| SCHEMBL4226261 | 0.77 | RXFP1 (0.35) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL15765069 | 0.75 | CYP3A4 (0.32) | RXFP1SIRT2 | |
| SCHEMBL29017447 | 0.75 | PARP1 (0.36) | KDM4EALDH1A1HPGD | |
| SCHEMBL4226441 | 0.74 | RXFP1 (0.43) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL28412403 | 0.73 | RXFP1 (0.40) | RXFP1KDM4EALDH1A1HPGDSIRT2 | |
| SCHEMBL28409899 | 0.71 | RXFP1 (0.39) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL28416923 | 0.71 | RAB9A (0.39) | RXFP1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| WO-2019143902-A2 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| WO-2014085607-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HDGF, HAVCR2 | RXFP1 4347/4885KDM4E 1806/4885ALDH1A1 2798/4885 |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | BCL6, MALT1, BCL3 | RXFP1 4859/4885KDM4E 609/4885ALDH1A1 214/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | RXFP1 4347/4885KDM4E 1806/4885ALDH1A1 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.